Clearside Biomedical (CLSD) Competitors $0.42 -0.03 (-5.77%) Closing price 04:00 PM EasternExtended Trading$0.43 +0.01 (+1.65%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLSD vs. MCRB, OKYO, SPRO, TARA, IOBT, GNLX, AVTX, IMRX, CNTB, and LIMNShould you be buying Clearside Biomedical stock or one of its competitors? The main competitors of Clearside Biomedical include Seres Therapeutics (MCRB), OKYO Pharma (OKYO), Spero Therapeutics (SPRO), Protara Therapeutics (TARA), IO Biotech (IOBT), Genelux (GNLX), Avalo Therapeutics (AVTX), Immuneering (IMRX), Connect Biopharma (CNTB), and Liminatus Pharma (LIMN). These companies are all part of the "pharmaceutical products" industry. Clearside Biomedical vs. Its Competitors Seres Therapeutics OKYO Pharma Spero Therapeutics Protara Therapeutics IO Biotech Genelux Avalo Therapeutics Immuneering Connect Biopharma Liminatus Pharma Clearside Biomedical (NASDAQ:CLSD) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation. Does the media prefer CLSD or MCRB? In the previous week, Clearside Biomedical had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 4 mentions for Clearside Biomedical and 2 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.94 beat Clearside Biomedical's score of 0.77 indicating that Seres Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clearside Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, CLSD or MCRB? Seres Therapeutics has higher revenue and earnings than Clearside Biomedical. Seres Therapeutics is trading at a lower price-to-earnings ratio than Clearside Biomedical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClearside Biomedical$1.66M20.29-$34.35M-$0.37-1.16Seres Therapeutics$126.32M1.15$140K-$4.60-3.62 Is CLSD or MCRB more profitable? Seres Therapeutics has a net margin of 0.00% compared to Clearside Biomedical's net margin of -665.19%. Clearside Biomedical's return on equity of 0.00% beat Seres Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Clearside Biomedical-665.19% N/A -124.15% Seres Therapeutics N/A -350.16%-67.69% Do insiders & institutionals hold more shares of CLSD or MCRB? 18.8% of Clearside Biomedical shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 6.7% of Clearside Biomedical shares are owned by company insiders. Comparatively, 4.7% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, CLSD or MCRB? Clearside Biomedical has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.9, suggesting that its stock price is 190% more volatile than the S&P 500. Do analysts recommend CLSD or MCRB? Clearside Biomedical currently has a consensus target price of $4.20, suggesting a potential upside of 879.02%. Seres Therapeutics has a consensus target price of $73.67, suggesting a potential upside of 342.18%. Given Clearside Biomedical's stronger consensus rating and higher probable upside, research analysts plainly believe Clearside Biomedical is more favorable than Seres Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearside Biomedical 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17Seres Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 SummaryClearside Biomedical beats Seres Therapeutics on 8 of the 15 factors compared between the two stocks. Get Clearside Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLSD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLSD vs. The Competition Export to ExcelMetricClearside BiomedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.68M$3.13B$5.68B$9.81BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-1.1620.7730.6825.56Price / Sales20.29370.75464.10116.64Price / CashN/A43.0338.2159.48Price / Book-0.698.608.996.13Net Income-$34.35M-$54.65M$3.25B$264.89M7 Day Performance5.25%6.55%4.78%2.67%1 Month Performance-48.15%9.54%6.80%3.11%1 Year Performance-59.34%14.08%30.61%25.14% Clearside Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLSDClearside Biomedical2.8037 of 5 stars$0.42-5.8%$4.20+892.9%-56.0%$33.21M$1.66M-1.1430Earnings ReportShort Interest ↑MCRBSeres Therapeutics3.2557 of 5 stars$14.53+2.3%$73.67+407.0%-6.7%$124.40M$126.32M-3.16330OKYOOKYO Pharma3.1547 of 5 stars$3.12-4.6%$7.00+124.4%+164.0%$122.99MN/A0.007Gap UpSPROSpero Therapeutics4.0498 of 5 stars$2.20+0.5%$5.00+127.3%+62.3%$122.44M$47.98M-1.72150Earnings ReportTARAProtara Therapeutics2.1655 of 5 stars$3.10-1.0%$20.50+561.3%+61.1%$120.76MN/A-1.8030Earnings ReportAnalyst RevisionIOBTIO Biotech3.03 of 5 stars$1.05-42.0%$9.33+788.9%-8.6%$119.24MN/A-0.7030News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Gap UpHigh Trading VolumeGNLXGenelux1.7626 of 5 stars$3.28+4.1%$17.75+441.2%+63.2%$118.99M$10K-3.8110News CoveragePositive NewsAnalyst RevisionAVTXAvalo Therapeutics3.2571 of 5 stars$9.01+0.9%$30.00+233.0%-6.6%$117.45M$440K0.0040Analyst ForecastShort Interest ↓Gap UpIMRXImmuneering3.7298 of 5 stars$3.21-1.2%$13.25+312.8%+181.5%$116.95M$320K-1.6460News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastCNTBConnect Biopharma3.3366 of 5 stars$2.05-1.0%$7.00+241.5%+83.8%$115.01M$26.03M0.00110News CoveragePositive NewsAnalyst ForecastShort Interest ↓Analyst RevisionLIMNLiminatus PharmaN/A$4.48+1.4%N/AN/A$114.99MN/A0.00N/APositive News Related Companies and Tools Related Companies Seres Therapeutics Competitors OKYO Pharma Competitors Spero Therapeutics Competitors Protara Therapeutics Competitors IO Biotech Competitors Genelux Competitors Avalo Therapeutics Competitors Immuneering Competitors Connect Biopharma Competitors Liminatus Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLSD) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access